We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

116 hedge funds and large institutions have $655M invested in Theravance Biopharma in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 28 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

79% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 28

46% more capital invested

Capital invested by funds: $449M → $655M (+$206M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 23

2.03% less ownership

Funds ownership: 82.56% → 80.53% (-2%)

3% less funds holding

Funds holding: 119 → 116 (-3)

76% less call options, than puts

Call options by funds: $978K | Put options by funds: $4.14M

Holders
116
Holders Change
-3
Holders Change %
-2.52%
% of All Funds
1.79%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
21
Increased
50
Reduced
28
Closed
23
Calls
$978K
Puts
$4.14M
Net Calls
-$3.17M
Net Calls Change
-$7.13M

Top Buyers

Rank Fund Capital Flow
1
WAM
Weiss Asset Management
Massachusetts
+$22.7M
2
MAP
Madison Avenue Partners
New York
+$15M
3
Morgan Stanley
Morgan Stanley
New York
+$8.28M
4
NM
Newtyn Management
New York
+$7.86M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.98M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$28.4M
2
CCM
Camber Capital Management
Massachusetts
-$17.4M
3
WP
Woodline Partners
California
-$12.2M
4
Millennium Management
Millennium Management
New York
-$8.04M
5
C
Chescapmanager
Maryland
-$5.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
101
Tower Research Capital (TRC)
New York
$19K -$15.3K -1,760 -50%
AF
102
Allworth Financial
California
$12K +$9.85K +1,130 New
TWA
103
TCI Wealth Advisors
Arizona
$6K +$4.49K +515 New
Rockefeller Capital Management
104
Rockefeller Capital Management
New York
$6K +$5.45K +625 New
CAPTRUST Financial Advisors
105
CAPTRUST Financial Advisors
North Carolina
$4K +$3.22K +369 New
WT
106
Whittier Trust
California
$3K – – –
S
107
SignatureFD
Georgia
$3K +$1.34K +154 +99%
Osaic Holdings
108
Osaic Holdings
Arizona
$2K – – –
Daiwa Securities Group
109
Daiwa Securities Group
Japan
$2K +$828 +95 +79%
PCG
110
Private Capital Group
Connecticut
$2K +$1.19K +136 New
QCG
111
Quadrant Capital Group
Ohio
$2K +$1.19K +137 +370%
PCFFS
112
Pacific Center for Financial Services
California
$1K – – –
Manulife (Manufacturers Life Insurance)
113
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$345 -$23K -2,640 -8%
RSCM
114
Rock Springs Capital Management
Maryland
– -$5.09M -687,500 Closed
CC
115
Clearline Capital
New York
– -$4.28M -577,800 Closed
TLP
116
Tri Locum Partners
New York
– -$956K -129,192 Closed
PVI
117
Pura Vida Investments
New York
– -$740K -100,000 Closed
HWAM
118
Hennion & Walsh Asset Management
New Jersey
– -$463K -62,546 Closed
BAM
119
Blueshift Asset Management
New Jersey
– -$393K -53,127 Closed
DC
120
Davenport & Co
Virginia
– -$252K -34,000 Closed
CCIA
121
Campbell & Co Investment Adviser
Maryland
– -$201K -27,200 Closed
LCM
122
Laurion Capital Management
New York
– -$201K -27,095 Closed
Principal Financial Group
123
Principal Financial Group
Iowa
– -$184K -24,799 Closed
OQS
124
Occudo Quantitative Strategies
Florida
– -$177K -23,958 Closed
PCM
125
Palisade Capital Management
New Jersey
– -$163K -22,000 Closed
2 3 4
5
6

TBPH Hedge Fund Activity: Q4 2021 in Review

116 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2021, worth a combined $655M — up 46% from $449M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of TBPH and 21 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 50 added.

The largest buyer was Weiss Asset Management, opening a new position worth an estimated $22.7M. The largest seller was Point72 Asset Management, cutting an estimated $28.4M.

  • 116 institutional investors held Theravance Biopharma (TBPH) as of Q4 2021, down from 119 in Q3 2021.
  • Funds reported $655M of Theravance Biopharma stock for Q4 2021, up 46% quarter-over-quarter.
  • 21 funds opened new Theravance Biopharma positions in Q4 2021 and 23 closed out, a net change of -2 holders.
  • The largest Theravance Biopharma buyer in Q4 2021 was Weiss Asset Management, an estimated $22.7M added.
  • The largest Theravance Biopharma seller in Q4 2021 was Point72 Asset Management, an estimated $28.4M sold.

Based on aggregated 13F filings for Q4 2021.